Conclusions The CFA analyses indicate that while the fit of the four-factor model for the PDQ fits, the model could be improved. Particularly concerning is the different factor-pathways for seven items, item 19's current low item-factor reliability, and the increased correlations between factors. In adult SLE patients, researchers and clinicians should be cautious in interpreting PDQ-20 results using the current four factors (subscales). Further validity analyses, including exploratory factor analyses, are needed.

CS-23 REMISSION AND LOW DISEASE ACTIVITY STATE ARE ASSOCIATED WITH A BETTER HEALTH-RELATED QUALITY OF LIFE IN SYSTEMIC LUPUS ERYTHEMATOSUS IN A PRIMARILY MESTIZO POPULATION

^{1,2}Manuel F Ugarte-Gil*, ¹Rocio V Gamboa-Cardenas, ¹Mariela Medina-Chinchón, ¹Francisco Zevallos, ¹Cristina Reátegui-Sokolova, ^{1,2}Claudia Elera-Fitzcarrald, ¹Victor Pimentel-Quiroz, ¹Jose Alfaro-Lozano, ^{1,3}Zoila Rodriguez-Bellido, ^{1,3}Cesar A Pastor-Asurza, ⁴Graciela S Alarcón, ^{1,3}Risto Perich-Campos. ¹Rheumatology Department. Hospital Guillermo Almenara Irigoyen. EsSalud; ²Universidad Científica del Sur; ³Universidad Nacional Mayor de San Marcos; ⁴School of Medicine, University of Alabama at Birmingham

10.1136/lupus-2018-lsm.58

Background Achieving remission or low lupus disease activity state (LDAS) in systemic lupus erythematosus (SLE) patients improves their prognosis in terms of damage accrual. But, there is not enough information about their impact on health-related quality of life (HRQoL). The aim of these analyses is to evaluate the association between remission or LDAS and HRQoL, after adjustment for possible confounders.

Methods The Almenara Lupus Cohort was started in 2012; all patients evaluated at the Rheumatology Department were invited to participate. Visits were performed every six months. Socioeconomic and clinical data were recorded at every visit. Disease activity was ascertained with the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), disease damage with the SLICC/ACR Damage Index (SDI) and HRQoL was measured with the LupusQoL. For these analyses, data from the baseline visit were included. Remission was defined as a SLEDAI-2K=0, prednisone ≤5 mg/d, immunosuppressants on maintenance dose, LDAS was defined as not on remission and a SLEDAI-2K≤4, prednisone ≤7.5 mg/d, immunosuppressants on maintenance dose. Univariable and multivariable linear regression models, adjusted by age at diagnosis, disease duration, socioeconomic status, antimalarial use, disease duration, time of exposure to prednisone, damage and comorbidities were performed. Due to the relatively small number of patients on remission, remission and LDAS were analyzed together.

Results Two hundred and eighty patients were included, 259 (92.5%) were female, mean age at diagnosis was 35.4 (SD=13.5) years, disease duration was 7.2 (6.5) years. Forty-five (16.1%) were on remission, 94 (33.6%) were on LDAS. Being on remission or LDAS was associated with a better HRQoL in the following domains, independently of possible confounders: physical health, planning, emotional health and body image. Univariable and multivariable analyses are depicted in table 1.

Conclusions Being on remission or LDAS is associated with a better HRQoL independently of possible confounders.

Abstract CS-23 Table 1 Association between remission/LDAS and HRQoL

	Univariable		Multivariable	
	B (CI95%)	p value	B (CI95%)	p value
Physical Health	8.68 (3.01; 14.34)	0.003	6.80 (1.78; 11.82)	0.008
Emotional Health	6.22 (0.71; 11.72)	0.027	5.76 (0.33; 11.19)	0.038
Body image	9.84 (4.52; 15.17)	<0.001	9.31 (4.03; 14.58)	0.001
Pain	6.74 (0.83; 12.64)	0.025	5.49 (−0.10; 11.09)	0.054
Planning	9.70 (2.91; 16.50)	0.005	7.89 (1.33; 14.42)	0.018
Fatigue	3.05 (−3.15; 9.26)	0.335	2.57 (−3.55; 8.69)	0.410
Intimate relationship	6.09 (−2.94; 15.13)	0.186	5.11 (−3.13; 13.36)	0.224
Burden to others	6.91 (−0.18; 14.00)	0.056	6.13 (−0.91; 13.16)	0.088

CS-24 ASSOCIATION OF LIPOPROTEIN SUBFRACTIONS AND GLYCOPROTEIN ACETYLATION WITH CORONARY PLAQUE BURDEN IN SYSTEMIC LUPUS ERYTHEMATOSUS

Monica M Purmalek, Philip M Carlucci, Amit K Dey, Maureen Sampson, Yenealem Temesgen-Oyelakin, Simantini Sakhardande, Joseph B Lerman, Alice Fike, Michael Davis, Jonathan H Chung, Taufiq Salahuddin, Zerai Manna, Sarthak Gupta, Marcus Y Chen, Sarfaraz Hasni, Nehal N Mehta, Alan T Remaley, Mariana J Kaplan*. *National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Bethesda, MD*

10.1136/lupus-2018-lsm.59

Background Subjects with Systemic Lupus Erythematosus (SLE) display an increased risk of atherosclerotic cardiovascular disease (CVD) that is not explained by Framingham Risk. This study sought to investigate the utility of nuclear magnetic resonance (NMR) spectroscopy measurements of serum lipoprotein particle counts and size and glycoprotein acetylation (GlycA) to predict coronary atherosclerosis in SLE.

Methods Coronary plaque burden was assessed in SLE subjects and healthy controls using coronary CT angiography. Lipoproteins and GlycA were quantified by NMR spectroscopy.

Results SLE subjects displayed statistically significant decreases in high-density lipoprotein (HDL) particle counts and increased very low density lipoprotein (VLDL) particle counts compared to controls. Non-calcified coronary plaque burden (NCB) negatively associated with HDL subsets, whereas it positively associated with VLDL particle counts in multivariate adjusted models. GlycA was significantly increased in SLE sera compared to controls. In contrast to high-sensitivity C-reactive protein, elevations in GlycA in SLE significantly associated with NCB and insulin resistance.

Conclusions SLE patients display a proatherogenic lipoprotein profile that may significantly contribute to the development of premature CVD. The results demonstrate that NMR measures of GlycA and lipoprotein profiles, beyond what is captured in routine clinical laboratory tests for lipids, could be a useful tool in assessing CVD risk in SLE patients.

CS-25 AN ANALYSIS OF HYDROXYCHLOROQUINE TREATMENT RESPONSE BY SEX IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

D Koh, K Beattie, K Legault, G Ioannidis, M Matsos*. *Department of Medicine, McMaster University, Hamilton, Ontario, Canada*

10.1136/lupus-2018-lsm.60

Background Systemic lupus erythematosus (SLE) has traditionally been viewed as a disease of women since the ratio of

affected women to men is 9:1. Historically, men with SLE were thought to have more severe disease and worse prognosis than women, however, a 2013 review did not find compelling evidence that damage, disease activity or mortality is affected by sex. It concluded that the only consistent sex-based differences in SLE were lower rates of select disease manifestations such as alopecia.

Given this, it is plausible that the two sexes also respond to treatment differently, yet very few men have been included in clinical trials. Only 4% (n=9) of participants in published

Abstract CS-25 Table 1 Characteristics of the CaNIOS cohort treated with HCQ by sex

	Total	Men	Women
CaNIOS Patients	n=499	n=57	n=442
Age, mean (SD) years	33.6 (17.9)	26.2 (16.4)	34.6 (17.9)
Age at SLE diagnosis, mean (SD) years	26.0 (15.5)	19.5 (13.3)	26.9 (15.6)
Disease duration, mean (SD) years	7.2 (7.8)	6.2 (6.5)	7.3 (7.9)
Alcohol Intake, N (%)	381 (76.4)	38 (66.7)	343 (77.6)
None	290 (76.1)	26 (68.4)	264 (77.0)
1–6 drinks/week	76 (19.9)	12 (31.6)	64 (18.7)
7–14 drinks/week	13 (3.4)	0	13 (3.8)
≥15 drinks/week	2 (0.5)	0	2 (0.6)
Smoking, N (%)	415 (83.2)	46 (80.7)	369 (83.5)
Never	322 (77.6)	38 (82.6)	284 (77.0)
≤5 cigarettes/day	16 (3.9)	2 (4.3)	14 (3.8)
>5 cigarettes/day	77 (18.6)	6 (13.0)	71 (19.2)
Number of DMARDs, N (%)	499(100)	57 (100)	442 (100)
None	281 (56.3)	31 (54.4)	250 (56.6)
1 DMARD	197 (39.5)	24 (42.1)	173 (39.1)
2 DMARDs	19 (3.8)	2 (3.5)	17 (3.8)
3 DMARDs	2 (0.4)	0	2 (0.5)
Prednisone, N (%)	218 (43.7)	32 (56.1)	186 (42.1)
None	1 (0.5)	0 (0)	1 (0.2)
Low (<7.5 mg PO daily)	82 (37.6)	9 (28.1)	73 (39.2)
Medium (7.5–15 mg PO daily)	77 (35.3)	14 (43.8)	63 (33.9)
High (>15 mg PO daily)	58 (26.6)	9 (28.1)	49 (26.3)
Ethnicity	498 (99.8)	57 (100)	441 (99.8)
Aboriginal	34 (6.8)	5 (8.8)	29 (6.6)
Arab/Middle Eastern	11 (2.2)	2 (3.5)	9 (2.0)
Asian	99 (19.9)	20 (35.1)	79 (17.9)
Black	39 (7.8)	2 (3.5)	37 (8.4)
Jewish	6 (1.2)	0	6 (1.4)
Latin/Hispanic	13 (2.6)	1 (1.8)	12 (2.7)
Pacific Islander	0	0	0
White	291 (58.4)	27 (47.4)	264 (59.9)
Don't know/Don't wish to answer	5 (1.0)	0	5 (1.1)
Annual Household Income, N (%)	371 (74.3)	43 (75.4)	328 (74.2)
< \$15 000	34 (9.2)	7 (16.3)	27 (8.2)
\$15,000 – \$29 999	45 (12.1)	8 (18.6)	37 (11.3)
\$30,000 – \$49 999	88 (23.7)	6 (14.0)	82 (25.0)
> \$50 000	204 (55.0)	22 (51.2)	182 (55.5)
Highest Education, N (%)	308 (61.7)	27 (47.4)	281 (63.6)
Did not complete high school	61 (19.8)	9 (33.3)	52 (18.5)
High school diploma	24 (7.8)	3 (11.1)	21 (7.5)
Vocational/technical school	54 (17.5)	3 (11.1)	51 (18.1)
Some college, no degree	49 (15.9)	4 (14.8)	45 (16.0)
College degree	104 (33.8)	7 (25.9)	97 (34.5)
Graduate/professional degree	16 (5.2)	1 (3.7)	15 (5.3)
DI score, mean(SD)	0.8 (1.3)	1.1 (1.8)	0.8 (1.2)
SLEDAI 2K score, mean(SD)	4.5 (4.7)	3.7 (4.9)	4.6 (4.7)

DMARD=disease modifying antirheumatic drug.